Shares of Theravance (THRX) soar over 18% in the post-trading session after coming off an all-day trading halt while awaiting the FDA's decision on its COPD inhaler Breo Ellipta. The stock most recently traded at $33.25, after being halted earlier this morning at $28.01, as the FDA voted solidly in favor of approval.
Shares of Theravance (THRX) soar over 18% in the post-trading session after coming off an...
From other sites
at CNBC.com (Jun 11, 2014)
at CNBC.com (Dec 6, 2013)
at CNBC.com (Sep 10, 2013)
at CNBC.com (Jun 24, 2013)
at CNBC.com (Apr 15, 2013)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs